SEC Tracker
Get the app

Possible new Dna X shares

SONMDilution

Known so far: no new shares from the prospectus covers read · shelf room about $4.2M · not yet read: converts, ATM.

Shelf room

  • Room today about $4.2M
  • One third of float $4.2M ($12.6M float, Jun 30, 2025)
  • Sold off it, 12 months nothing
How this is worked out

Shelf room about $4.2M on the S-3 of Jul 9, 2025: the baby-shelf rule (public float under $75M) caps sales at one third of the $12.6M public float stated as of Jun 30, 2025, $4.2M, nothing sold off it in the last 12 months. Sources: S-3 Jul 9, 2025, effective Jul 18, 2025 · public float, as of Jun 30, 2025.

What could become new Dna X (SONM) shares: warrants and options and RSUs, each with the 10-Q, 10-K, S-1 or 424B filing it comes from.

Dna X dilution ladder

Every source of new shares on record, from the filings that created it.

1.5M outstanding; up to 1.6M fully diluted, +7%

  1. Outstandingas of Aug 18, 2026 (10-Q filed Aug 19) · share count on the cover page
    1.5M
  2. Warrants63K10-Q Oct 31, 2025 · securities left out of diluted EPS
    +63K
  3. Options and RSUs36K options, 0 RSUs10-Q Oct 31, 2025 · equity note
    +36K

Not stated in the filings we read: an ATM program, convertible notes.

Counts, sizes and prices as stated in each filing; the fully diluted count is arithmetic on them. Dollars become shares only at a price a filing states. Not advice.

Financing terms to know

None found in filings since Oct 31, 2025.

Each term is quoted from the exhibit it comes from; numbers are as stated in the filing. A flag describes a financing term. It is not investment advice.

Shares outstanding

1.5M

Nov 2024 to Aug 2026: from 271K to 1.5M. Adjusted for the 1-for-18 reverse split by Oct 28, 2025: each earlier count is divided by the ratio of every split after it.

From the share count on the cover of each 10-Q and 10-K, dated as each cover states.